MétaCan
Menu
Back to cohort
Record W4410641492 · doi:10.1093/jnci/djaf100

Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines

2025· article· en· W4410641492 on OpenAlexafffund
Brooke E. Wilson, Kristin Wright, Manju Sengar, Richard Sullivan, Sallie‐Anne Pearson, Michael Bartoň, Bishal Gyawali, Elisabeth G.E. de Vries, Lorenzo Moja, C.S. Pramesh

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2025
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicEconomic and Financial Impacts of Cancer
Canadian institutionsQueen's University
FundersQueen's UniversityWorld Health Organization
KeywordsMedicineConcordanceCancerEssential medicinesHepatocellular carcinomaInternal medicineFamily medicineOncologyPublic healthPathology

Abstract

fetched live from OpenAlex

BACKGROUND: The World Health Organization (WHO) Essential Medicines List (EML) and resource-stratified guidelines both prioritize high-value medicines. We compared the 2023 EML cancer medicines list with global cancer statistics, examined the proportion of EML therapies recommended by resource-stratified guidelines, and identified gaps that merit evaluation by the WHO EML Committee. METHODS: We compared the 2023 EML medicines for adult cancers with cancer incidence and mortality data from GLOBOCAN 2022. We cross-referenced the EML with 2 resource-stratified guidelines (National Comprehensive Cancer Network [NCCN] and National Cancer Grid [NCG] of India) and evaluated preferred treatments in resource-stratified guidelines that were not recommended by the EML. RESULTS: The 2023 EML included 64 cancer medicines for 219 tumor-specific indications. The greatest number of medicines are listed for leukemia (37/219 [17%]) and lymphoma (33/219 [15%]). Although some common cancers (eg, hepatocellular carcinoma) have no EML-listed medicines because of the low clinical benefit, we identified some cancers (eg, esophageal, gastric) with effective therapies that the EML Committee should evaluate for inclusion. Cancers with no listed medicines make up 34% of cancer deaths globally. Among EML indications with an NCCN resource-stratified guideline, 42% (35/84) and 73% (62/84) were recommended by the NCCN Basic and Core Guidelines, respectively. Among EML indications with an NCG resource-stratified guideline, 163 of 196 (83%) and 175 of 196 (89%) were recommended by the NCG Essential and Optimal guidelines, respectively. CONCLUSIONS: We identified some effective medicines that should be evaluated for inclusion in the WHO EML. Prioritization of cancer medicines was similar between the EML and NCG India but discordant between with NCCN resource-stratified guideline.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.263
Threshold uncertainty score0.605

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.336
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicEconomic and Financial Impacts of CancerFrench-language works237,207